Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis
Authors:
- Andrew SpencerAndrew Spencer
- Maria GavriatopoulouMGMaria Gavriatopoulou
- Daniel CoriuDCDaniel Coriu
- Norma C. GutiérrezNorma C. Gutiérrez
- Fernando EscalanteFEFernando Escalante
- Dorotea Beatriz Eugenia FantlDFDorotea Beatriz Eugenia Fantl
- Roman HájekRHRoman Hájek
- Fernanda SeguroFSFernanda Seguro
- Gurbakhash KaurGKGurbakhash Kaur
Open Access
- 14 November 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (22) , 5814-5827
Abstract
Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We report results from MEDICI, a global, minimally invasive, prospective study evaluating t(11;14) status in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM). MEDICI enrolled adult patients (≥18 years) with MM with bone marrow (BM) aspirates collected at diagnosis and/or disease relapse. The primary objective was to determine t(11;14) prevalence in patient BM samples using fluorescent in situ hybridization (FISH) with plasma cell enrichment. Samples from 525 patients (NDMM, n = 306; RRMM, n = 219) were analyzed for t(11;14), with 498 patients (95%) having successful BM FISH test. Prevalence of t(11;14) was 22.1% (110/498 patients; 95% confidence interval [CI], 18.5-26.0) in the overall patient population, 18.8% (56/298 patients; 95% CI, 14.5-23.7) in NDMM, and 27.0% (54/200 patients; 95% CI, 21.0-33.7) in RRMM. Patients with t(11;14)-positive MM were evenly distributed across disease stages (stage I, 24.1%; stage II, 20%; stage III, 21.3%); however, higher rates were observed in African American patients (RRMM odds ratio [OR], 7.27, 95% CI, 1.33-39.83; P = .022) and light-chain only disease (NDMM OR, 3.02, 95% CI, 1.33-6.87; P = .008). Chromosome 1q abnormalities occurred more often in the absence of t(11;14); however, higher frequency of mutation in the plasma cell differentiation regulator IRF4 was detected in t(11;14) presence. In conclusion, the results from MEDICI demonstrated reproducible t(11;14) detection with a real-world prevalence of 22.1% in MM. This trial was registered at www.ClinicalTrials.gov as #NCT04721002.Keywords
This publication has 45 references indexed in Scilit:
- The dynamic functions of IRF4 in B cell malignanciesClinical and Experimental Medicine, 2022
- Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM RegistryClinical Lymphoma Myeloma and Leukemia, 2022
- Diagnosis and Management of Multiple MyelomaJAMA, 2022
- Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)American Journal of Hematology, 2021
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2020
- Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2016
- t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcomeLeukemia Research, 2013
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013Mayo Clinic Proceedings, 2013
- International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsCancer, 2010
- Genetic events in the pathogenesis of multiple myelomaBest Practice & Research Clinical Haematology, 2007